

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HighTide Therapeutics, Inc.

君圣泰医药

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2511)

HIGHTIDE THERAPEUTICS ANNOUNCES ACCEPTANCE OF NEW DRUG APPLICATION FOR HTD1801 BY CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by HighTide Therapeutics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business development of the Group.

The board of directors (the “**Board**”) of the Company announces that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for HTD1801 for the treatment of Type 2 Diabetes Mellitus (T2DM). This marks the first NDA submitted by HighTide Therapeutics and a major milestone on its path towards product commercialization.

HTD1801 has completed three multicenter, randomized, double-blind, controlled Phase III clinical trials for the T2DM indication – all of which met their primary endpoints as well as multiple secondary endpoints. Across these studies, HTD1801 consistently demonstrated improvements in multiple dimensions of the cardiovascular-kidney-metabolic (CKM) spectrum, including glycemic control, lipid metabolism, inflammatory markers, and renal function. These results highlight the potential of HTD1801 to deliver comprehensive, multi-system therapeutic benefits through a single therapy.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that HTD1801 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
HighTide Therapeutics, Inc.
Dr. LIU Liping
Executive Director and Chief Executive Officer

Hong Kong, March 10, 2026

As at the date of this announcement, the Board comprises Dr. LIU Liping and Ms. YU Meng as executive Directors; Dr. ZHU Xun, Mr. MA Lixiong and Mr. JIANG Feng as non-executive Directors; and Mr. TAN Bo, Dr. LI Jin and Mr. HUNG Tak Wai as independent non-executive Directors.